18 recruiting, 17 completed, 9 unknown, 5 terminated. 33 Phase 1, 23 Phase 2, 4 Not applicable, 2 Early Phase 1, 1 Phase 4.
Follow Refractory Cancer: new trials by email Literature Review of Refractory Cancer trials Research Report on Refractory Cancer
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Pedi-STAR: Surface Target Antibody-drug Conjugate (ADC) Antigen Expression in Relapsed/Refractory Pediatric Solid and CNS Tumors Bulk RNA Sequencing, Immunohistochemistry (IHC) - CNS Tumor, Solid Tumor | Not applicable | Not yet recruiting | Dana-Farber Cancer Institute | 130 | 2026-09-01 | 2026-08-31 |
| A Study to Investigate Safety and Effectiveness of Tacabrutideg (BGB-16673) in Combination With Other Agents in Participants With Relapsed or Refractory B-Cell Malignancies Tacabrutideg, Sonrotoclax, Zanubrutinib - B-cell Malignancy, Relapsed Cancer | Phase 1 / Phase 2 | Recruiting | BeOne Medicines | 80 | 2024-11-27 | 2026-09-11 |
| Plan Development for Giving Teclistamab in the Outpatient Setting Teclistamab, Tocilizumab - Multiple Myeloma, Relapsed Cancer | Phase 4 | Recruiting | University Health Network, Toronto | 15 | 2024-11-19 | 2025-12-10 |
| Allogeneic NKG2DL-targeting CAR γδ T Cells (CTM-N2D) in Advanced Cancers (ANGELICA) Allogeneic NKG2DL-targeting Chimeric Antigen Receptor-grafted γδ T Cells (CTM-N2D) - Cancer, Malignancy | Phase 1 | Recruiting | CytoMed Therapeutics Pte Ltd | 12 | 2024-11-19 | 2024-11-22 |
| A Study of RO7617991 in Patients With Locally Advanced or Metastatic MAGE-A4-Positive Solid Tumors RO7617991, Tocilizumab - Refractory Cancer, Recurrent Cancer | Phase 1 | Withdrawn | Genentech, Inc. | 2024-09-30 | 2024-09-03 | |
| Optimal Precision TherapIes to CustoMISE Care in Childhood and Adolescent Cancer Paxalisib, Opdualag, Irinotecan (drug) - Childhood Cancer, Childhood Solid Tumor | Phase 1 / Phase 2 | Recruiting | Australian & New Zealand Children's Haematology/Oncology Group | 90 | 2024-07-10 | 2026-01-28 |
| Zanubrutinib With Pemetrexed to Treat Relapsed/Refractory Primary and Secondary Central Nervous System (CNS) Lymphomas Pemetrexed, Zanubrutinib, Autologous Stem Cell Transplant (ASCT) - Primary Central Nervous System Lymphoma, Secondary Central Nervous System Lymphoma | Phase 2 | Recruiting | Baptist Health South Florida | 15 | 2024-04-25 | 2026-03-03 |
| Autologous CAR-T Cells Targeting CSPG4 in Relapsed/Refractory HNSCC Cyclophosphamide, Fludarabine, Cell Therapy - Head and Neck Cancer, Relapse | Phase 1 | Recruiting | UNC Lineberger Comprehensive Cancer Center | 33 | 2024-04-05 | 2026-11-05 |
| A Dose Escalation and Expansion Study of [177Lu]Lu-SN201 in Participants With Advanced Cancer [177Lu]Lu-SN201 - Solid Tumor, Metastatic Cancer | Phase 1 / Phase 2 | Recruiting | Spago Nanomedical AB | 90 | 2023-12-06 | 2025-11-20 |
| Individualized Treatments in Adults With Relapsed/Refractory Cancers Drug Sensitivity Test (DST) - Refractory Cancer, Relapsed Cancer | Not applicable | Completed | Case Comprehensive Cancer Center | 36 | 2023-11-20 | 2026-07-06 |
| Safety and Efficacy of Epcoritamab With Gemcitabine, Dexamethasone, and Cisplatin (GDP) Salvage Chemotherapy in Relapsed Refractory Large B-cell Lymphoma AutoSCT OR CAR T-cell Therapy, GDP, Epcoritamab - Large Cell Lymphoma, Diffuse, Relapsed Cancer | Phase 2 | Recruiting | Vijendra Singh | 35 | 2023-10-31 | 2026-11-05 |
| A Study of Avutometinib for People With Solid Tumor Cancers Avutometinib - Refractory Cancer, CNS Tumors | Phase 1 | Completed | Memorial Sloan Kettering Cancer Center | 3 | 2023-10-20 | 2026-11-04 |
| Leflunomide or Combination of MEK Inhibitor and Hydroxychloroquine for Refractory Patients With RAS Mutations Leflunomide, The combination of MEK inhibitor + hydroxychloroquine( plaquenil) ± bevacizumab - RAS Mutation, Ras (Kras or Nras) Gene Mutation | Phase 2 | Unknown | N.N. Petrov National Medical Research Center of Oncology | 20 | 2023-10-03 | 2024-01-29 |
| Study of Allogeneic Blood-derived Natural Killer Cells to Evaluate Safety and Tolerability in Cancer Refractory to Conventional Therapy SNK02 - Pathologically Confirmed Cancer Refractory to Conventional Therapy, Refractory Cancer | Phase 1 | Completed | NKGen Biotech, Inc. | 6 | 2023-08-23 | 2024-11-20 |
| IMA402 T Cell-Engaging Receptor Molecule (TCER®) in Recurrent and/or Refractory Solid Tumors IMA402, IMA402 and checkpoint inhibitor, IMA402 and chemotherapy - Refractory Cancer, Recurrent Cancer | Phase 1 / Phase 2 | Recruiting | Immatics Biotechnologies GmbH | 400 | 2023-08-09 | 2026-09-01 |
| A Study of SNS-101 (Anti VISTA) Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors SNS-101 (anti-VISTA), Cemiplimab - Solid Tumor, Adult, Advanced Solid Tumor | Phase 1 / Phase 2 | Completed | Sensei Biotherapeutics, Inc. | 98 | 2023-05-31 | 2026-09-02 |
| A Study of MQ710 With and Without Pembrolizumab in People With Solid Tumor Cancer MQ719, Pembrolizumab - Cutaneous Squamous Cell Carcinoma, SCC - Squamous Cell Carcinoma | Phase 1 | Recruiting | Memorial Sloan Kettering Cancer Center | 56 | 2023-05-04 | 2026-08-12 |
| Phase 1 Study Evaluating the Safety and PK of ADU-1805 in Advanced Solid Tumors ADU-1805, Pembrolizumab - Solid Tumor, Adult, Metastatic Solid Tumor | Phase 1 | Recruiting | Sairopa B.V. | 130 | 2023-04-03 | 2026-11-03 |
| A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor Malignancies GV20-0251, GV20-0251 and Pembrolizumab [KEYTRUDA®] - Solid Tumor, Adult, Refractory Cancer | Phase 1 / Phase 2 | Recruiting | GV20 Therapeutics | 365 | 2023-03-23 | 2025-02-13 |
| A Study of HST-1011 Given as Monotherapy and in Combination With an Anti-PD1 Antibody HST-1011, Cemiplimab - Solid Tumor, Adult, Relapsed Cancer | Phase 1 / Phase 2 | Active not recruiting | HotSpot Therapeutics, Inc | 77 | 2023-03-15 | 2025-02-04 |
Showing 20 of 56. Sign in to see all of them.
Neoplasms (56) · Recurrence (31) · Neoplasm Metastasis (10) · Carcinoma, Non-Small-Cell Lung (5) · Colorectal Neoplasms (5) · Melanoma (5) · Pancreatic Neoplasms (4) · Central Nervous System Neoplasms (3) · Prostatic Neoplasms (3) · Sarcoma (3) · Brain Neoplasms (2) · Breast Neoplasms (2) · Carcinoma, Merkel Cell (2) · Endometrial Neoplasms (2) · Head and Neck Neoplasms (2)
Pathologic Processes (37) · Pathological Conditions, Signs and Symptoms (37) · Disease Attributes (31) · Neoplasms by Site (21) · Neoplasms by Histologic Type (18) · Hemic and Lymphatic Diseases (10) · Neoplastic Processes (10) · Neoplasms, Germ Cell and Embryonal (8) · Neoplasms, Nerve Tissue (8) · Neuroectodermal Tumors (8) · Urogenital Diseases (8) · Urogenital Neoplasms (8) · Digestive System Diseases (7) · Digestive System Neoplasms (7) · Gastrointestinal Diseases (7)
pembrolizumab (9) · Irinotecan (3) · 3-(5-fluorobenzofuran-3-yl)-4-(5-methyl-5H-(1,3)dioxolo(4,5-f)indol-7-yl)-pyrrole-2,5-dione (2) · Bendamustine Hydrochloride (2) · Cyclophosphamide (2) · Paclitaxel (2) · Rituximab (2) · Temozolomide (2) · cemiplimab (2) · ibrutinib (2) · tocilizumab (2) · zanubrutinib (2) · Afatinib (1) · Albumin-Bound Paclitaxel (1) · Antibodies, Monoclonal (1)
University Health Network, Toronto (4) · Immatics US, Inc. (3) · Actuate Therapeutics Inc. (2) · Australian & New Zealand Children's Haematology/Oncology Group (2) · Dana-Farber Cancer Institute (2) · Immatics Biotechnologies GmbH (2) · Memorial Sloan Kettering Cancer Center (2) · NKGen Biotech, Inc. (2) · National Cancer Institute (NCI) (2) · Samsung Medical Center (2) · Vanderbilt-Ingram Cancer Center (2) · AVEO Pharmaceuticals, Inc. (1) · Baptist Health South Florida (1) · BeOne Medicines (1) · Biomea Fusion Inc. (1)
United States (34) · Canada (7) · Germany (6) · Australia (5) · China (3) · South Korea (3) · Spain (3) · Belgium (2) · Israel (2) · Netherlands (2) · New Zealand (2) · Brazil (1) · France (1) · Italy (1) · Japan (1)
Cedrik Britten, M.D. (2) · Maryjo Gilmer, PhD (2) · Aaron Mansfield, MD (1) · Alison O'Neill, MD (1) · Anand D Jeyasekharan, Dr (1) · Arthur DeCillis, MD (1) · Brian Turpin, DO (1) · Brigitte C Widemann, M.D. (1) · Cedrik Britten, MD (1) · Christine Chen, Dr. (1) · Daniel D Von Hoff, MD (1) · Daniel Morgenstern, Dr (1)
PMID 24327518, PMID 27424289, PMID 28053024, PMID 28672195, PMID 29383130, PMID 29846250, PMID 31101621, PMID 31533931, PMID 31831767, PMID 31882719, PMID 20179235, PMID 26486517, PMID 30405781, PMID 30975030, PMID 31401903, PMID 31894292, PMID 32580982, PMID 34927159, PMID 35417717, PMID 35815408, PMID 36754451, PMID 36882456, PMID 37214210, PMID 37751186, PMID 38844796, PMID 38898768, PMID 39572395, PMID 40205198, PMID 40209140, PMID 41075807, PMID 41981308, PMID 42219399, PMID 42399266
2023 (1), P30CA012197 (1), R01CA296807 (1), R21HD097757 (1)